New Market Research Report: Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022

From: Fast Market Research, Inc.
Published: Thu May 02 2013

GlobalData has released its new PharmaPoint Drug Evaluation report, "Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer's Betaseron/Betaferon (IFNB-1b), Biogen's Avonex (IFNB-1a) and Merck's Rebif (IFNB-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Full Report Details at

Rebif (interferon beta-1a; Merck Serono [EMD Serono in the US]) is an SC-administered, interferon-based DMT that is indicated for the treatment of patients with RRMS and CIS. The drug is co-promoted in the US by EMD Serono and Pfizer. Similar to Avonex, Rebif is produced from genetically engineered CHO cells using recombinant DNA technology, and the 166 amino acid sequence of Rebif is identical to that of natural fibroblast-derived human IFNB (Rebif package insert, 2003). As with the other currently approved interferon agents, the exact mechanism of action of Rebif in MS is not fully elucidated.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).


* Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Rebif including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Rebif for the top ten countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Rebif performance

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »